RxDoctor Payments Data

Jessica Deppen, APRN

Family · Oklahoma City, OKNPI 1659774131

Payments from drug & device makers

$1,577in general payments, 2019–2025

Across 133 payments — averaging $11.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$327
  • Sunovion Pharmaceuticals Inc.$219
  • Lilly USA, LLC$180
  • Johnson & Johnson$157
  • Sumitomo Pharma America, Inc.$124
  • Xeris Pharmaceuticals, Inc.$54
  • plus $517 from 18 others

What the payments were for

  • Food & beverage$1,577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,577 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$196,499
Medicare patients
543
Services billed
2,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$153,062
OzempicSemaglutide61$62,086
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$34,674
Nurtec OdtRimegepant Sulfate27$32,082
MounjaroTirzepatide28$29,774
JardianceEmpagliflozin41$24,718
MyrbetriqMirabegron55$23,974
VraylarCariprazine Hcl15$20,943
RexultiBrexpiprazole15$18,963
FarxigaDapagliflozin Propanediol35$18,243
XareltoRivaroxaban33$16,747
LinzessLinaclotide29$15,988
Memantine Hcl326$10,842
JanuviaSitagliptin Phosphate36$10,560
Potassium Chloride486$10,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$62,08661 claims
AbbVieVraylar, Linzess$327$36,93144 claims
Lilly USA, LLCMounjaro$180$29,77428 claims
AstraZenecaFarxiga, Brilinta$43$24,17249 claims
Otsuka America Pharmaceutical, Inc.Rexulti$36$18,96315 claims
Johnson & JohnsonXarelto$157$16,74733 claims
NovartisEntresto$15$8,63712 claims
Sumitomo Pharma America, Inc.Gemtesa$124$7,63516 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$49$7,61315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →